BACKGROUND: Despite many advances in assisted reproductive techniques (ART), little is known about preferences for technological developments of @entity1 undergoing fertility treatments. The aims of this study were to investigate the preferences of infertile @entity1 undergoing ART for controlled ovarian stimulation ( @entity6862 ) treatments; to determine the utility values ascribed to different attributes of @entity6862 treatments; and to estimate @entity1 's willingness to pay (WTP) for @entity6862 . METHODS: A representative sample of ambulatory @entity1 ready to receive, or receiving, @entity6862 therapies for @entity249 were recruited from seven specialized private centres in six autonomous communities in Spain. Descriptive, inferential and conjoint analyses (CA) were used to elicit preferences and WTP. Attributes and levels of @entity6862 treatments were identified by literature review and two focus groups with experts and @entity1 . WTP valuations were derived by a combination of double-bounded (closed-ended) and open questions and contingent ranking methods. RESULTS: In total, 160 @entity1 [mean (standard deviation; SD) age: 35.8 (4.2) years] were interviewed. Over half of the @entity1 (55.0%) had a high level of education (university degree), most (78.8%) were married and half (50.0%) had an estimated net income of >   1502 per month and had paid a mean (SD)    1194.17 (   778.29) for their most recent hormonal treatment. The most frequent causes of @entity249 were related to @entity6847 (50.3%). In 30.6% of cases, there were two causes of @entity249 . The maximum WTP for @entity6862 treatment was    800 (median) per cycle; 35.5% were willing to pay an additional    101-   300 for a 1-2% effectiveness gain in the treatment. Utility values (CA) showed that effectiveness was the most valued attribute (39.82), followed by costs (18.74), safety (17.75) and information sharing with physicians (14.93). CONCLUSIONS: WTP for @entity6862 therapies exceeds current cost. Additional WTP exists for 1-2% effectiveness improvement. Effectiveness and costs were the most important determinants of preferences, followed by safety and information sharing with physicians.

Willingness to pay and conjoint analysis to determine XXXX 's preferences for ovarian stimulating hormones in the treatment of @entity249 in Spain.

@entity1 :: ('9606', 'Species') :: ['participants', 'women', 'patients'] @entity6862 :: ('CHEBI:16573', 'Chemical') :: ['COS'] @entity6847 :: ('MESH:C567467', 'Disease') :: ['sperm abnormalities'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']
@entity1 :: (9606,Species) :: ['women']
